Spero Therapeutics Profit Margin

The latest profit margin for SPRO is 26.65% as of March 2026. That compares with -1.63% in the prior-year period — up 116.4% year over year. That is above the Healthcare sector average of 15.58%. Investors often review this figure alongside Spero Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPRO's profit margin moved from -1.63% to 26.65% — a 116.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Spero Therapeutics's valuation or profitability profile.

Against Healthcare companies, SPRO currently prints 26.65% for profit margin, while the sector average sits near 15.58%. That is roughly 71.0% above the sector mean. Large gaps often invite a closer look at Spero Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Spero Therapeutics converts resources into returns. At 26.65%, SPRO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1.63% in the prior-year period — up 116.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SPRO's profit margin (26.65%), review year-over-year change from -1.63%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.